α-葡萄糖苷酶抑制剂市场、机会、成长动力、产业趋势分析与预测，2024-2032

全球 α-葡萄糖苷酶抑制剂市场价值为 33 亿美元，预计 2024 年至 2032 年复合年增长率为 3.2%，受全球 2 型糖尿病盛行率激增的推动。

随着全球人口老化和久坐生活方式的增加，糖尿病发生率不断上升，尤其是在发展中国家。不断扩大的患者群体增加了对有效治疗的需求，例如α-葡萄糖苷酶抑制剂。这些抑制剂透过减缓肠道中碳水化合物的吸收来控制血糖，发挥至关重要的作用。此外，人们对早期糖尿病诊断和管理的认识不断提高，加上政府和医疗机构采取的积极措施，正在推动市场的成长。

由于肥胖和不健康的生活方式等因素，全球对第 2 型糖尿病的关注日益增加，凸显了对有效治疗的需求。作为背景，国际糖尿病联盟 (IDF) 在其 2022 年糖尿病图谱中报告称，约 5.37 亿 20-79 岁成年人患有糖尿病，约占该年龄组的 10.5%。预测显示，到 2030 年，这一数字将增加至 6.43 亿，到 2045 年将增至 7.83 亿。

α-葡萄糖苷酶抑制剂产业依据药物类型、适应症、类型、配销通路和地区进行分类。

市面上将药物类型分为阿卡波糖、米格列醇、伏格列波糖和复方药物。阿卡波糖细分市场处于领先地位，到 2023 年将达到 15 亿美元。阿卡波糖作为麦芽糖酶和蔗糖酶等酵素的竞争性抑制剂，可减缓碳水化合物的消化，导致餐后血糖适度上升。它在增强血糖控制方面的有效性，并且没有显着的体重增加或严重的低血糖，巩固了其作为医疗保健专业人员青睐的选择的地位。

α-葡萄糖苷酶抑制剂的通路包括医院药局、零售药局和线上平台。 2023 年，医院药局处于领先地位，预计2024 年至2032 年复合年增长率为2.9%。情况下。通常，这些药房是药物的主要获取点，特别是对于需要密切监测和调整剂量的复杂糖尿病患者。

2023年，北美α-葡萄糖苷酶抑制剂市场估值为14亿美元，预计2024年至2032年复合年增长率为2.8%。率的上升2 型糖尿病和肥胖症。对糖尿病管理的认识的提高和先进的医疗设施加强了这种领导力。此外，主要製药公司积极参与α-葡萄糖苷酶抑制剂的研发，推动了市场的成长。

目录

第 1 章：方法与范围

第 2 章：执行摘要

第 3 章：产业洞察

• 产业生态系统分析
• 产业影响力
  • 成长动力
    • 2 型糖尿病盛行率上升
    • 越来越多地采用口服抗糖尿病药物
    • 糖尿病管理意识不断增强
  • 产业陷阱与挑战
    • 不良副作用
    • 来自替代疗法的竞争
• 成长潜力分析
• 监管环境
• 管道分析
• 波特的分析
• PESTEL分析

第 4 章：竞争格局

• 介绍
• 公司矩阵分析
• 主要市场参与者的竞争分析
• 竞争定位矩阵
• 战略仪表板

第 5 章：市场估计与预测：按药物类型，2021 - 2032 年

• 主要趋势
• 阿卡波糖
• 米格列醇
• 伏格列波糖
• 组合药物

第 6 章：市场估计与预测：按指标划分，2021 - 2032 年

• 主要趋势
• 2型糖尿病
• 糖尿病前期

第 7 章：市场估计与预测：按类型，2021 - 2032

• 主要趋势
• 品牌化
• 通用的

第 8 章：市场估计与预测：按配销通路，2021 - 2032 年

• 主要趋势
• 医院药房
• 零售药局
• 网路药局

第 9 章：市场估计与预测：按地区，2021 - 2032

• 主要趋势
• 北美洲
  • 我们
  • 加拿大
• 欧洲
  • 德国
  • 英国
  • 法国
  • 西班牙
  • 义大利
  • 荷兰
  • 欧洲其他地区
• 亚太地区
  • 日本
  • 中国
  • 印度
  • 澳洲
  • 韩国
  • 亚太地区其他地区
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 拉丁美洲其他地区
• 中东和非洲
  • 沙乌地阿拉伯
  • 南非
  • 阿联酋
  • 中东和非洲其他地区

第 10 章：公司简介

• Alkem Laboratories Ltd.
• Bayer AG
• Cipla Limited
• Dr. Reddy's Laboratories Ltd.
• Emcure Pharmaceuticals Ltd.
• Lupin Ltd.
• Merck and Co.
• Novartis AG
• Sanofi SA
• Sun Pharmaceutical Industries Ltd.
• Takeda Pharmaceutical Company
• Torrent Pharmaceuticals Ltd.
• Unichem Laboratories Ltd.

The Global Alpha-Glucosidase Inhibitors Market was valued at USD 3.3 billion and is projected to grow at a 3.2% CAGR from 2024 to 2032, fueled by the surging global prevalence of type 2 diabetes.

With an aging global population and increasingly sedentary lifestyles, diabetes rates are climbing, especially in developing nations. This expanding patient demographic amplifies the demand for effective treatments, such as alpha-glucosidase inhibitors. These inhibitors play a crucial role in managing blood glucose by slowing carbohydrate absorption in the intestines. Furthermore, heightened awareness about early diabetes diagnosis and management, alongside proactive measures from governments and healthcare entities, is driving the market's growth.

The rising global concern over type 2 diabetes, spurred by factors like obesity and unhealthy lifestyles, underscores the demand for effective treatments. For context, the International Diabetes Federation (IDF) reported in its 2022 Diabetes Atlas that around 537 million adults aged 20-79 were living with diabetes, constituting roughly 10.5% of that age group. Projections suggest this number will escalate to 643 million by 2030 and 783 million by 2045.

The Alpha-Glucosidase Inhibitors Industry is classified based on drug type, indication, type, distribution channel and region.

The market categorizes drug types into acarbose, miglitol, voglibose, and combination drugs. Leading the pack, the acarbose segment accounted for USD 1.5 billion in 2023. Acarbose's dominant market position stems from its proven efficacy in type 2 diabetes management. Acting as a competitive inhibitor for enzymes like maltase and sucrase, acarbose slows carbohydrate digestion, resulting in a moderated rise in post-meal blood glucose. Its effectiveness in enhancing glycemic control, without significant weight gain or severe hypoglycemia, has cemented its status as a favored option among healthcare professionals.

Distribution channels for alpha-glucosidase inhibitors include hospital pharmacies, retail pharmacies, and online platforms. In 2023, hospital pharmacies took the lead, and are projected to grow at a CAGR of 2.9% from 2024 to 2032. Their dominance is attributed to their pivotal role in diabetes management, especially in inpatient scenarios where precise glucose control is paramount. Often, these pharmacies serve as the primary access point for medications, especially for patients with intricate diabetes cases necessitating close monitoring and dosage adjustments.

In 2023, the North American market for alpha-glucosidase inhibitors was valued at USD 1.4 billion, with projections indicating a growth rate of 2.8% CAGR from 2024 to 2032. North America's leading role in the alpha-glucosidase inhibitors market is due to rising rates of type 2 diabetes and obesity. Increased awareness about diabetes management and advanced healthcare facilities reinforce this leadership. Additionally, the proactive engagement of major pharmaceutical companies in researching and developing alpha-glucosidase inhibitors propels the market's growth.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising prevalence of type 2 diabetes
    • 3.2.1.2 Growing adoption of oral antidiabetic drugs
    • 3.2.1.3 Growing awareness of diabetes management
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 Adverse side effects
    • 3.2.2.2 Competition from alternative therapies
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Pipeline analysis
• 3.6 Porter's analysis
• 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Competitive analysis of major market players
• 4.4 Competitive positioning matrix
• 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Drug Type, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Acarbose
• 5.3 Miglitol
• 5.4 Voglibose
• 5.5 Combination drugs

Chapter 6 Market Estimates and Forecast, By Indication, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Type 2 diabetes mellitus
• 6.3 Pre-diabetes

Chapter 7 Market Estimates and Forecast, By Type, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Branded
• 7.3 Generic

Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 Hospital pharmacies
• 8.3 Retail pharmacies
• 8.4 Online pharmacies

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Spain
  • 9.3.5 Italy
  • 9.3.6 Netherlands
  • 9.3.7 Rest of Europe
• 9.4 Asia Pacific
  • 9.4.1 Japan
  • 9.4.2 China
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 South Korea
  • 9.4.6 Rest of Asia Pacific
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Rest of Latin America
• 9.6 Middle East and Africa
  • 9.6.1 Saudi Arabia
  • 9.6.2 South Africa
  • 9.6.3 UAE
  • 9.6.4 Rest of Middle East and Africa

Chapter 10 Company Profiles

• 10.1 Alkem Laboratories Ltd.
• 10.2 Bayer AG
• 10.3 Cipla Limited
• 10.4 Dr. Reddy's Laboratories Ltd.
• 10.5 Emcure Pharmaceuticals Ltd.
• 10.6 Lupin Ltd.
• 10.7 Merck and Co.
• 10.8 Novartis AG
• 10.9 Sanofi SA
• 10.10 Sun Pharmaceutical Industries Ltd.
• 10.11 Takeda Pharmaceutical Company
• 10.12 Torrent Pharmaceuticals Ltd.
• 10.13 Unichem Laboratories Ltd.